Use of Analog and Human Insulin in a European Hemodialysis Cohort With Type 2 Diabetes: Associations With Mortality, Hospitalization, MACE, and Hypoglycemia.
Fiche du document
- doi: 10.1053/j.ajkd.2023.05.010
- issn: 0272-6386
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/doi/10.1053/j.ajkd.2023.05.010
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/pmid/37657634
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/eissn/1523-6838
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/urn/urn:nbn:ch:serval-BIB_B10BC32DD44F0
info:eu-repo/semantics/openAccess , CC BY 4.0 , https://creativecommons.org/licenses/by/4.0/
Sujets proches
People Man Humanity (Human beings) Human race Mankind Homo sapiens Humankind Humans Kidney dialysis Blood dialysis Renal dialysis Extracorporeal dialysis Blood--DialysisCiter ce document
T. Ebert et al., « Use of Analog and Human Insulin in a European Hemodialysis Cohort With Type 2 Diabetes: Associations With Mortality, Hospitalization, MACE, and Hypoglycemia. », Serveur académique Lausannois, ID : 10.1053/j.ajkd.2023.05.010
Métriques
Partage / Export
Résumé
Poor glycemic control may contribute to the high mortality rate in patients with type 2 diabetes receiving hemodialysis. Insulin type may influence glycemic control, and its choice may be an opportunity to improve outcomes. This study assessed whether treatment with analog insulin compared with human insulin is associated with different outcomes in people with type 2 diabetes and kidney failure receiving hemodialysis. Retrospective cohort study. People in the Analyzing Data, Recognizing Excellence and Optimizing Outcomes (AROii) study with kidney failure commencing hemodialysis and type 2 diabetes being treated with insulin within 288 dialysis facilities between 2007 and 2009 across 7 European countries. Study participants were followed for 3 years. People with type 1 diabetes were excluded using an established administrative data algorithm. Treatment with an insulin analog or human insulin. All-cause mortality, major adverse cardiovascular events (MACE), all-cause hospitalization, and confirmed hypoglycemia (blood glucose